OmniAb(US:OABI)2025-05-09 01:11Business Highlights - OmniAb had 95 active partners as of March 31, 2025[13, 15] - The company reported 378 active programs as of March 31, 2025, with over 98% having contracted future economics to OmniAb[17, 19] - OmniAb had 33 active clinical programs and approved products as of March 31, 2025[20, 22] - One new OmniAb-derived program, Genmab's GEN1078, entered a first-in-human clinical trial in Q1[24] - Post-discovery stage programs grew by 39% over the last 24 months[25] - OmniAb launched the xPloration Partner Access Program, expecting it to be accretive to earnings and cash flow in both the short- and long-term[11, 67] Financial Performance - Q1 2025 total revenue increased to $4.2 million compared to $3.8 million in Q1 2024, driven by license and milestone revenue[73, 75, 79] - License and milestone revenue was $2.0 million in Q1 2025, compared to $0.7 million in Q1 2024[79] - Service revenue decreased to $1.9 million in Q1 2025 from $2.8 million in Q1 2024[79] - Q1 2025 net loss was $18.2 million, compared to a net loss of $19.0 million in Q1 2024[79] - OmniAb is affirming revenue guidance of $20 million to $25 million for 2025[82] - Operating expense guidance revised to be in the range of $85 million to $90 million for 2025[82]